CALGARY, June 15, 2016 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has dosed the first patient in its Phase 1 clinical trial for ZEN-3694 in metastatic Castration Resistant Prostate Cancer ("mCRPC") patients. In the Phase 1 trial, Zenith will be evaluating the safety, pharmacokinetics, and efficacy of ZEN-3694 as a single agent and in combination with the current standard of care enzalutamide. Zenith has also implemented a rich translational program to measure target modulation and to identify potential biomarkers for selecting patient subsets most likely to benefit from BET inhibition.
"We are excited about reaching this important milestone for Zenith and the development of ZEN-3694 in mCRPC patients with significant unmet need. We are working with prominent clinical investigators and the Prostate Cancer Clinical Trial Consortium ("PCCTC") who collectively have been instrumental in developing the leading drugs for treating mCRPC. ZEN-3694 is well differentiated and has shown a superior safety and efficacy profile in pre-clinical studies. This puts Zenith at the forefront of development of BET Bromodomain inhibitors for the treatment of cancer" stated Mr. Donald McCaffrey, President and Chief Executive Officer.
Zenith has also developed strong pre-clinical rationale for developing ZEN-3694 in other oncology indications and intends to expand its clinical program in the near future.
Additional trial details and updates can be found at: www.clinicaltrials.gov.
Corporate Update Webcast
Zenith announces it will be hosting a corporate update via webcast on Monday, June 20, 2016 at 11:00 am MT / 1:00 pm ET. Mr. Donald McCaffrey, President and Chief Executive Officer will provide a general corporate update and overview of recent activities.
To join the webcast, please visit: http://services.choruscall.ca/links/zenith20160620.html
Date: Monday, June 20, 2016
Time: 11:00 am MT/1:00 pm ET
Duration: 30 minutes
A presentation will accompany and be available via the webcast. Alternatively, the presentation will also be available immediately prior to the conference call start time of 11:00am MT on the Company's website at: http://www.zenithepigenetics.com/newsroom/presentations-&-publications
To call-in please dial:
mCRPC is a major unmet medical need due to its widespread occurrence and incurable status. Current standard of care for this disease is androgen receptor (AR) antagonists and/or androgen synthesis inhibitors (enzalutamide). While most patients display an initial response to these agents, eventually even responding patients develop drug resistance via various mechanisms. Recent evidence suggests that BET bromodomain inhibitors (BETi) can be efficacious in mCRPC patients that are resistant to current therapies.
Zenith Epigenetics Corp. is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith's bromodomain (BET) inhibitors are being advanced for several oncology indications and have the potential to impact multiple additional non-oncology diseases as well. The lead compound, ZEN-3694, is in clinical development for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
To learn more, please visit: www.zenithepigenetics.com.
SOURCE Zenith Epigenetics Corp.